We thought that this difference occurred because of the inherent genomic alterations and molecular signature present in A549 (p53 wild-type) and H1299 (p53-deficient) cells, which are both lung adenocarcinoma cells 41, and the differential changes in the transcriptome after cisplatin treatment may also account for the different proliferation response. This evidence concerns the gene TP53 and lung adenocarcinoma.